Cost-effectiveness of melioidosis vaccines as determined by incidence, cost, protective efficacy and protective duration.


<p>It was assumed that policy makers in Thailand were willing to pay $3,000 for an additional QALY gained. Areas in blue indicate where the vaccine is considered cost-effective in the Thai context. The protective efficacy (PE) and protective duration (PD) of the vaccine were considered as homogenous for all routes of disease acquisition. Percentage reduction of PE in this figure was considered as a combination of reduction in both disease incidence and mortality rate.</p

    Similar works

    Full text


    Available Versions